The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma

Fernando Alegre, Amanda R. Ormonde, Dayn R. Godinez, Anuradha Illendula, John H. Bushweller, Luke Anthony Wittenburg

Research output: Contribution to journalArticle

Abstract

Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface molecules with little clear therapeutic benefit. Transcription factors and protein interactions represent underdeveloped areas of therapeutic drug development. We have utilized allosteric inhibitors of the core binding factor transcriptional complex, comprised of core binding factor beta (CBFβ) and RUNX2, in four canine osteosarcoma cell lines Active inhibitor compounds demonstrate anti-tumour activities with concentrations demonstrated to be achievable in vivo while an inactive, structural analogue has no activity. We show that CBFβ inhibitors are capable of inducing apoptosis, inhibiting clonogenic cell growth, altering cell cycle progression and impeding migration and invasion in a cell line-dependent manner. These effects coincide with a reduced interaction between RUNX2 and CBFβ and alterations in expression of RUNX2 target genes. We also show that addition of CBFβ inhibitors to the commonly used cytotoxic chemotherapeutic drugs doxorubicin and carboplatin leads to additive and/or synergistic anti-proliferative effects in canine osteosarcoma cell lines. Taken together, we have identified the interaction between components of the core binding factor transcriptional complex, RUNX2 and CBFβ, as a potential novel therapeutic target in canine osteosarcoma and provide justification for further investigations into the anti-tumour activities we describe here.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Core Binding Factor beta Subunit
osteosarcoma
Osteosarcoma
Canidae
therapeutics
Core Binding Factors
dogs
transcription factors
cell lines
Cell Line
neoplasms
Dogs
Therapeutics
drugs
Neoplasms
doxorubicin
Carboplatin
Pharmaceutical Preparations
Doxorubicin
cell growth

Keywords

  • canine sarcoma
  • core-binding factor beta
  • novel therapeutic targets
  • osteosarcoma
  • RUNX2
  • transcription factor

ASJC Scopus subject areas

  • veterinary(all)

Cite this

The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma. / Alegre, Fernando; Ormonde, Amanda R.; Godinez, Dayn R.; Illendula, Anuradha; Bushweller, John H.; Wittenburg, Luke Anthony.

In: Veterinary and Comparative Oncology, 01.01.2019.

Research output: Contribution to journalArticle

@article{d955f75e6b344adbb99cc905acf8e0b3,
title = "The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma",
abstract = "Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface molecules with little clear therapeutic benefit. Transcription factors and protein interactions represent underdeveloped areas of therapeutic drug development. We have utilized allosteric inhibitors of the core binding factor transcriptional complex, comprised of core binding factor beta (CBFβ) and RUNX2, in four canine osteosarcoma cell lines Active inhibitor compounds demonstrate anti-tumour activities with concentrations demonstrated to be achievable in vivo while an inactive, structural analogue has no activity. We show that CBFβ inhibitors are capable of inducing apoptosis, inhibiting clonogenic cell growth, altering cell cycle progression and impeding migration and invasion in a cell line-dependent manner. These effects coincide with a reduced interaction between RUNX2 and CBFβ and alterations in expression of RUNX2 target genes. We also show that addition of CBFβ inhibitors to the commonly used cytotoxic chemotherapeutic drugs doxorubicin and carboplatin leads to additive and/or synergistic anti-proliferative effects in canine osteosarcoma cell lines. Taken together, we have identified the interaction between components of the core binding factor transcriptional complex, RUNX2 and CBFβ, as a potential novel therapeutic target in canine osteosarcoma and provide justification for further investigations into the anti-tumour activities we describe here.",
keywords = "canine sarcoma, core-binding factor beta, novel therapeutic targets, osteosarcoma, RUNX2, transcription factor",
author = "Fernando Alegre and Ormonde, {Amanda R.} and Godinez, {Dayn R.} and Anuradha Illendula and Bushweller, {John H.} and Wittenburg, {Luke Anthony}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/vco.12526",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma

AU - Alegre, Fernando

AU - Ormonde, Amanda R.

AU - Godinez, Dayn R.

AU - Illendula, Anuradha

AU - Bushweller, John H.

AU - Wittenburg, Luke Anthony

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface molecules with little clear therapeutic benefit. Transcription factors and protein interactions represent underdeveloped areas of therapeutic drug development. We have utilized allosteric inhibitors of the core binding factor transcriptional complex, comprised of core binding factor beta (CBFβ) and RUNX2, in four canine osteosarcoma cell lines Active inhibitor compounds demonstrate anti-tumour activities with concentrations demonstrated to be achievable in vivo while an inactive, structural analogue has no activity. We show that CBFβ inhibitors are capable of inducing apoptosis, inhibiting clonogenic cell growth, altering cell cycle progression and impeding migration and invasion in a cell line-dependent manner. These effects coincide with a reduced interaction between RUNX2 and CBFβ and alterations in expression of RUNX2 target genes. We also show that addition of CBFβ inhibitors to the commonly used cytotoxic chemotherapeutic drugs doxorubicin and carboplatin leads to additive and/or synergistic anti-proliferative effects in canine osteosarcoma cell lines. Taken together, we have identified the interaction between components of the core binding factor transcriptional complex, RUNX2 and CBFβ, as a potential novel therapeutic target in canine osteosarcoma and provide justification for further investigations into the anti-tumour activities we describe here.

AB - Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface molecules with little clear therapeutic benefit. Transcription factors and protein interactions represent underdeveloped areas of therapeutic drug development. We have utilized allosteric inhibitors of the core binding factor transcriptional complex, comprised of core binding factor beta (CBFβ) and RUNX2, in four canine osteosarcoma cell lines Active inhibitor compounds demonstrate anti-tumour activities with concentrations demonstrated to be achievable in vivo while an inactive, structural analogue has no activity. We show that CBFβ inhibitors are capable of inducing apoptosis, inhibiting clonogenic cell growth, altering cell cycle progression and impeding migration and invasion in a cell line-dependent manner. These effects coincide with a reduced interaction between RUNX2 and CBFβ and alterations in expression of RUNX2 target genes. We also show that addition of CBFβ inhibitors to the commonly used cytotoxic chemotherapeutic drugs doxorubicin and carboplatin leads to additive and/or synergistic anti-proliferative effects in canine osteosarcoma cell lines. Taken together, we have identified the interaction between components of the core binding factor transcriptional complex, RUNX2 and CBFβ, as a potential novel therapeutic target in canine osteosarcoma and provide justification for further investigations into the anti-tumour activities we describe here.

KW - canine sarcoma

KW - core-binding factor beta

KW - novel therapeutic targets

KW - osteosarcoma

KW - RUNX2

KW - transcription factor

UR - http://www.scopus.com/inward/record.url?scp=85071269113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071269113&partnerID=8YFLogxK

U2 - 10.1111/vco.12526

DO - 10.1111/vco.12526

M3 - Article

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -